The Cannabis Company That Won't Mix Work With Pleasure
A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully.
For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users.
“If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said.
Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market.
“It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.”
And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021.
For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).
Empower your financial future with 'Investing Is Your Superpower' by Shinobu Hindert. Learn how to take control of your finances. No economics degree required
Inflation is still high, and economic activity is starting to slow down. But before you start to panic about stagflation, wait to see this week’s jobs report.
With buildings responsible for over 40% of emissions worldwide, the CEO of Kelvin breaks down how its technology can be used to retrofit traditional radiators.
After battling inflation for years, now U.S. consumers have to prepare for stagflation, and, unfortunately, it could be more complicated to fix than a typical
